FDA Approves Olaparib Tablets for Maintenance Treatment

August 21, 2017 5:23 pm

On August 17, 2017, the U.S. Food and Drug Administration (FDA) granted regular approval to olaparib tablets (Lynparza) for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, who are in a complete … Read more

Olaparib Maintenance Therapy Boosts PFS in Ovarian Cancer

March 21, 2017 4:23 am

Maintenance treatment with olaparib (Lynparza, AstraZeneca) can significantly extend progression-free survival (PFS) in a subset of patients with ovarian cancer.

The results of a phase 3 trial showed that in patients with germline¬†BRCA-mutated, platinum-sensitive, relapsed ovarian … Read more

Murine Study Finds Potential Boost For Ovarian Cancer Drug Olaparib

February 1, 2017 8:12 pm

Researchers from the Chinese Academy of Sciences have discovered that the metabolic enzyme phosphoglycerate mutase 1 (PGAM1) helps cancer cells repair their DNA and found that inhibiting PGAM1 sensitizes tumors to the cancer drug Olaparib (Lynparza). Their findings in the … Read more